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PRECIS
Neuroleptics have proven effective for the overall treatment of schizophre-
nia . The neuroleptic therapy of schizophrenia, however, has been limited by
tardive dyskinesia and by the relative inability of neuroleptics to ameliorate th e
negative symptoms of schizophrenia. Intensive research has been conducted to
identify atypical neuroleptics which would not cause TO and which would ha ve
relatively greater efficacy in treating negative symptoms. Based upon animal
models of T D and negative symptoms, four neuroleptics have been identified
which may have these properties: c1ozapine, thioridazine, sulpiride, and molin-
done. Clinical studies of TD suggest that these four potentially atypical agents
may have lower dyskinetic potential than typica l neuroleptics. Additionally,
clinical studies of negative symptoms suggest that molindone and sulpiride, bu t
not clozapine or thioridazine may preferentially treat depressive-like negative
schizophrenic symptomatology. The atypical effects of c1ozapine, thioridazine,
sulpiride and molindone, suggest that they may have a distinct place in th e
pharmacotherapy of schizophrenia.
INTRODUCTION
Since their d iscovery in the mid-1950s, neuroleptic drugs have proven to
be safe and effective treatments for schizophrenia . Schizophrenic subjects
treated with neuroleptics have been shown to have improved overall functionin g
and a decreased need for hosp italizat ion versus non-treated controls. The
pharmacotherapy of schizophrenia with neuroleptics, however, has proven to be
limited by at least two factors. First, neuroleptics increase the rate at which
schizophrenic patients develop the long-term potentially irreversible and inca-
pacitating movement disorder, tardive dyskinesia (TO). Second, neuroleptics
have proven relative ly ineffective in treating the negative symptoms of schizo-
phrenia (e.g. blunted affect, poverty of speech and of ideation) (1,2) and ma y
induce akinetic symptoms which closely resemble the negative schizophrenic
symptoms (3,4). Intensive research has been conducted over the past three
decades on both a basic scie nce and a clinical leve l to determine whether or not
these two lim ita tions are inevitable concomitants of neuroleptic therapy. Basic
studies using animal models of TO and negative symptoms now suggest that
several agents do behave differently from traditional neuroleptics (e.g. chlor-
prom azine , haloperidol) an d may indeed possess atypica l clinical properties
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including a relatively decreased dyskinetogenic potential and/ or a relatively
increased efficacy in treating negative symptoms. Four such potentially atyp ica l
agents have been identified. Clozapine, a compound of th e dibenzodiazepine
class, has been the best studied and is considered th e prototype atypical
neuroleptic. Long-term clinical studies have suggested that clozapine has low to
absent dyskinetogenic potential. Clozapine, however , remains available in th is
country only on an experimental basis because of associated agranulocyto sis.
Thioridazine, a widely used neuroleptic of the piperidine phenothiazine class,
appears to have c1ozapine-like effects in basic models of TD although to a more
limited extent. Detailed clinical studies have not been conducted th at woul d
allow a determination of the dyskinetogenic potential of thioridazine. Cases of
TD presumably related to thioridazine treatment have been reported and th e
possible decreased dyskinetogenic potential of thioridazine has been much
debated (5,6). Sulpiride, a substituted benzamide, and molindone, an indol ic
derivative, are other neuroleptics with novel chemical structures. These agents,
at least in some dose ranges, behave similarly to clozapine in basic models of TD.
While definitive clinical studies have yet to be performed for th ese agents,
studies using masking paradigms suggest that these agents also may have
decreased dyskinetogenic potential compared with traditional neurolept ics.
Sulpiride and molindone behave differently from traditional neuroleptics in
animal models of negative symptoms as well, suggesting that th ey may also have
improved efficacy in treating negative symptoms.
BASIC STUDIES
The role of dopaminergic hyperactivity in schizophrenic pathophysio logy
has now been well established. Agents which increase brain dopaminergic
transmission worsen overall schizophrenic symptomatology. The poten cy with
which neuroleptic agents ameliorate schizophrenic symptoms correlat es with
their potency in blocking dopaminergic transmission at D2 type dopami ne
receptors (7,8). Less well established, however, is the role of the various brain
dopaminergic systems in contributing to schizophrenic pathoph ysiology and the
clinical response to neuroleptics. Three separate dopaminergic systems have
been identified in forebrain. Two of these, the mesocortical and mesolimbic
systems arise from the midbrain ventral tegmental area (area Al 0) and innervate
the neocortex (e.g. frontal cortex, cingulate cortex) and limbic system (e.g .
nucleus accumbens) respectively. The third arises from the substantia nigra
(area A9) and innervates the neostriatum. The me socortical and mesolimbic
systems are thought to subserve cogn it ion and affective regulation whil e th e
nigrostriatal system, which has been implicated in th e pathoph ysiology of
Parkinson's disease (9) and Huntington's chorea (10), is thought to be inv ol ved
mainly with regulation of brain motoric systems. The th erapeutic ac tions of
neuroleptics and their behavioral side effects ma y result primarily from th e ir
actions in the mesolimbic and mesocortical systems while the d yskinet ogen ic
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effects of neuroleptics are likel y to be mediated by th ei r actions on the
nigrostriatal system (7,8). As a result , agents whi ch se lec tive ly spare th e nigro-
striatal system should have a relatively decreased risk of inducin g T D. Several
model systems have been used in an attempt to measure th e effec ts of neurolep-
tics on th e mesocortical and mesolimbic systems versus th eir effects on the
nigrostriatal system. Three of th ese paradigms in particul ar have gained
widespread acceptance (Table I). Studies using th ese paradi gms suggest that the
proposed atypica l agents c1ozapine, thioridazin e , sulp ir ide, an d molindone
induce less inhibition o f nigrostriatal dopaminergic transm ission than tradi-
tional agents. These agents, therefore, might have a relativel y decreased risk for
inducing motoric side effects and, in particular, T D.
Behavioral Supersensitivity
The first model of TD is bas ed upon th e observation tha t in rats the
dopaminergic agent amphetamine produces a characteristic syndro me of stereo-
typies and hyperactivity. Amphetamine-induced ste re o typ ies have been shown
to be mediated by th e nigrostriatal system whil e amphetamine-induced hyperac-
tivity is mediated by th e mesolimbic system (11, 12) . Typ ica l neu rolept ic agents
TABLE 1.
Summary of Animal Models for Tardive Dyskinesia
ac u te :
Paradigm
Behavioral
supe rsensit ivity
Receptor
supersensitivity
T ypical Neuroleptics Atypical Ne uroleptics
! ampe tam ine induced ! amphet amine induced
hyperactivity hyperact ivity
! amphet amine induced N.C. amphe ta mine in-
ste reotypy duced stereotypy
chro nic: i amphet amine ind uced i amphetamine ind uced
stereotyp y stereotypy
i ampheta mine induced .C. amphe ta m ine in-
ste reotypy duced stereotypy
chro nic: i receptor density - nu- i recepto r den sity - nu-
cleus accumbens cleu s accumben s
i receptor density - st r ia- N.C. receptor density
tum striatum
Depolarization
ina ctivation
acute: i firing rate - A9
i firing rate - Al 0
chro nic: ! firing rat e - A9
! firing rate - Al 0
N .C. or ! firing rat e - A9
i firin g rat e - A l 0
N. C. fir ing rat e - A9
! fir ing rat e - Al 0
Effects of acute and chronic treatments with typical and atypica l neuroleptics on
amphetamine-induced hyperactivity and stereotypies, on dopamine recepto r den sity in
nucleus accumbens and striatum and o n the firing rate of neurons in A9 and Al 0
midbrain dopaminergic nuclei . N.C. indicates no change.
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acutely block both amphetamine-induced ste reo typies and hyperact ivity sug-
gesting that they induce a net dopaminergic block ade in both th e n igrostriatal
and the mesolimbic systems. The prototypical atypi cal agent c1ozapine, con-
versely, inhibits only amphetamine-induced hyperactivity whil e paradoxically
enhancing amphetamine-induced stereotypies (13-17). Clozapine , th ere fore ,
appears to block dopaminergic transmission only in th e mesolimbic system whi le
sparing or possibly enhancing nigrostriatal dopaminergic transmi ssio n . T hio-
ridazine (16-18), sulpir ide (13 ,16,17,19-21 ) and molindone (22) also potentia te
amphetamine-induced stereotypies suggesting that th ese agents a lso spare
nigrostriatal system functioning.
Following chronic treatment with typical neuroleptic agents, rat s show a n
increased sensitivity for developing amphetamine- induced ste reotypies and
hyperactivity. This increased sensitivity is thought to result fr om a co mpensa-
tory supersensitivity of nigrostriatal and mesolimbic dopaminergic receptors
following prolonged blockade. In contrast to typical agents, clozap ine has been
shown to induce supersensitivity only of amp heta mine-ind uced hyperact ivity
and not of amphetamine-induced ste ro typ ies (14 ,1 5) suggest ing that it does not
induce long-term changes in nigrostriatal system functioning. T h ioridazine (23),
sulpiride (19) and molindone (24,25) either do not induce supe rsens it ivity to
amphetamine-induced stereotypies in rats following chronic treatment o r do so
with considerably less potency than equivalent dosages o f traditional agents .
While a relationship between behavio ral supersens it ivity to am pheta mi ne and
TD ha s ye t to be demonstrated, th e relative ability of th ese proposed atypical
agents to spare the nigrostriatal system suggests that th ese agents may be less
likely than typical agents to induce long-term cha nge s in th e nigro striaral
system.
Receptor Supersensitivity
In order to investigate whether dopamine receptor superse ns itiv ity under-
lies the neuroleptic-induced behavioral superse nsitivity, dopamine recepto rs in
the striatum and nucleus accumbens have been stud ied d ir ectl y usin g radiola-
belled agents which bind specificall y to D2-type dopamine receptors (e.g.
[3H]spiperone). Traditional neuroleptics have been shown to induce a n increase
in the number of D2 receptors in the striatum following days to weeks of
continuous treatment. By contrast clozap ine ( 14 ,15 ,26), su lpir ide (26, 27) and
molindone (24) do not induce supersensitivity ofstriatal D2 receptors, suggesting
again that these agents affect nigrostriatal dopaminergic transmi ssion to a lesse r
extent than traditional agents do.
Shortly after the discovery of neuroleptic-induced supersensitivity of
striatal D2 receptors it was proposed that dyskinetic movements result from the
interaction of endogenous dopamine with the supe rsensitive D2 recepto rs
(28,29). Recent findings, however, have called this th eory into quest ion (30).
First, receptor supersensitivity can develop after a single ad min istration of
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neuroleptics whereas dyskinetic symptoms a r ise only after prolonged adm inis-
tration. Second, receptor supersensitivit y develops in all subjects tested, while
TD devel ops sporadicall y. Third, receptor supersens it ivity remains reversible
upon withdrawal of neuroleptics while TD may persist inde fin itely. Finally,
detailed post-mortem studies have fail ed to find a n association be tween st riatal
D2 receptor densit y a nd a prior history of T D (3 1). D2 receptor supersensitivity,
th erefore , is probably not mechan isticall y related to TD. Receptor su persensi-
tivity may howeve r be seen as a step in the cascade of events wh ich u ltimately
results in th e expression of dyskinetic sym pto ms .
Depolarization Inactivation
In add ition to th eir behavioral a nd b ioch emica l effects, neuroleptics have
been shown to directl y affect th e fir ing patterns of dopaminergic neurons in the
A9 and Al 0 midbrain nuclei, whi ch originate in the nigrostriat al and rneso lim-
bic /mesocortical pathways respecti vely. Block ade of dopaminergic transmission
depolarizes neurons in both th e A9 and Al 0 nucle i, leadin g to an ac ute increase
in their firing rate (3 2). Following chronic neurolept ic-induced depolarization,
howe ver, th ese neurons grad ua lly lose their coord inate d pa ttern of firing and
over time become com p lete ly quiescent. Direct ad m in ist ra tion of -y-am inobu-
tyri c ac id (GA BA) , an in h ibito ry transmi tter, ca n resto re activity to these
inact ivated neurons suggesting th at th e ir in acti vati on is due to chron ic depolar-
izat ion (33). Neuroleptic-ind uced depolarization of A l 0 neurons is thought to
underlie the antipsychot ic effec ts of neuroleptics and possibl y th e ir behavioral
side e ffec ts whil e doplarization inacti vation of A9 neurons may be the first step
in a sequence of even ts leading to T D (34). In this theory (35), it is hypo thesized
that block ade o f postsynaptic striata l dopamine receptors leads to a decrease in
the ac tivi ty of th e normall y inhibitory GA BA- med iate d st riatonigral feedback
pathway whi ch lead s to a depolarizati on of A9 neurons a nd an ac ute increase of
st r ia ta l dopamine release . Following prolonged dopaminergic blockade , how-
e ver, the A9 neurons become incapable of sus ta in ing the increased firing rate
a nd become grad ua lly inacti ve leading to a decline in striatal dopamine release .
As long as th e st r ia to n igral GABAergic ne urons remain intact, th e process
remains reversible . Dopaminerg ic denerva tion of th e GA BAergic neurons,
however, appears to place an adaptive st ress upon them wh ich over t ime may
facilitate th eir degeneration . Degene rati o n of GABAergic str iatonigra l neurons
ha s been implicat ed in th e pathophysiology of Huntington 's chorea (10) and
Wilso n's di sease , co ndi tions wh ich present with dys kinet ic symptoms clinically
ind isti nguis hab le from those of T D, and so may be the fina l co mmon pathway
fo r the ge nerat ion of dyskinetic movements. Experimenta l destruc tion of the
str ia tonigra l pathway in animals leads to depolarizat ion inacti vation in A9 and to
the development of dysk inetic movements (36). Cebus monkeys who are exposed
to neuroleptics over a period of years can dev elop dysk inesias which closely
resem b le those of T D (3 7). Mo nk eys who de velop dysk inesias have bee n shown
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to have significantly lower levels of GABA in the substantia nigra th an mon keys
who do not (38) suggesting that a failure of GABAergic neurons to adapt to
functional dopaminergic denervation may be etiologically relat ed to th e de ve l-
opment of dyskinesias. Human post-mortem studies o f sch izoph renics have
likewise demonstrated a decreased striatal GABA lev el in subjects with a prior
history of TD versus those without (31). 0 differences in dopamine recepto r
numbers were found in these patients. These findings suggest th at while
depolarization inactivation of A9 neurons does not directl y underlie dyski netic
movements. It may be the first of a cascade of events whi ch ultimately resul ts in
TD. Agents which do not induce depolarization ina ctivation of A9 neurons,
therefore, should be relatively without dyskinetogenic potential.
Administration of the traditional neuroleptics ch lo rp ro mazine, hal oper i-
dol and fluphenazine has been shown to lead to an ac ute increase in th e firi ng
rate of neurons in both A9 and A I 0 followed by a sustained depolarizati on
inact ivation of these neurons (39-41). By contrast, clozapine (33,39,40), thi o-
ridazine (39), sulpiride (39) and molindone (39) have been shown not to induce
depolarization inactivation in A9. Acute administration of th ese agents increases
the firing rate of neurons in Al 0 but not in A9 while th eir chronic ad m inist ra-
tion leads to a decrease in the firing rates of neurons only in Al O. Clozapine an d
molindone (41) have also been shown to reverse th e inhibition of firing rates
induced by ch ronic haloperidol at the dosages used in th ese stu d ies. Clozapine ,
thioridazine, sulpiride and molindone therefore , appear not to inhibit nigro-
striatal dopaminergic transmission and so ma y be less likely than tradi tion a l
agents to induce TD. l-Sulpiride, the "active" isomer o f su lp ir ide, has bee n
shown to induce depolarization inactivation of A9 wh en administered o n its own
whereas d-sulpiride, the " inactive" isomer, has no effec t (33). Fo r su lp iride,
therefore, at ypicality may depend upon administering racemate l-sul p ir ide
which is the clinically available form of the d rug.
Possible Mechanisms ofN eu roleptic Atypicality
The exact mechanism by which atypical neuroleptics spare th e nigrostriat al
system remains a question of intense debate. One common a bility of all putat ive
atypicals is to selectively increase presynaptic dopamine release in th e str iatum.
Presynaptic dopamine synthesis and release can be assayed either by mea suri ng
the activity of tyrosine hydroxylase, the rate limiting en zyme responsibl e for
dopamine synthesis, or by directly measuring the levels of dopamine metabo-
lites. Using these assays, it has been found that c1ozapine, thioridazine, sulp iride
and molindone all increase dopamine synthesis and release in the striatum but
that they differ in the mechanism by which they do so. Clozapine and thiorida-
zine have been found to stimulate tyrosine hydroxylase activity via non-
haloperidol sensitive receptors (43) and to increase DA metabolite levels via a
transsynaptic mechanism (44). Molindone (44) and sulpiride (45 ), co nverse ly,
appear to operate via a homosynaptic mechanism . The at ypical effec ts of
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clozapine and thioridazine , th erefore , are probably mediated via thei r actions on
th e non-dopaminergic brain systems whi ch regulate dopaminergic transmission
whil e th e at ypical effec ts of molindone a nd sulp ir ide are most p robably mediated
via their direct e ffec ts on th e dopaminergic te rm inals.
Clozapine and to a lesser ex te n t thioridazin e have been shown to have
relatively low potencies of ac tion at brain O2 receptors and rela tively high
potencies at D. dopaminergic receptors, at adrenergic recepto rs, a t m usca r in ic
cholinergic receptors and at serotonergic receptors (46,47). It rema ins unclear
whi ch if any of these rec eptors mediates the atypi cal effec ts of clozapine and
thioridazin e . Most attention has been foc used upon a nt i-cholinergic and anti-
adrenergic effec ts (48, 49) . More recently it has been suggested that the a nti-
ser ito ne rgic potency of clozap ine may cont r ibu te to its a typica lity as we ll. In one
study, LSD, a sero to ne rgic ag onist , potentiated the hyperact ivity induced by the
dopaminergic ag ent apomorphine. Clozapine but not haloperidol or su ipiride
inhibited the LSD-induced potentiation of apomorph ine hyperacti vity (50)
suggesting that clozapine has a distinct effec t on brain serotonergic systems
whe n compared with other neuroleptics. Thioridazine was no t ex plicitly te sted
in this paradi gm. Striatum (5 I) and subs tantia nigra (32) receive in nervation
from brain serotonerg ic systems suggesting that seroto ni n may play a modula-
tory role in nigrostriatal syste m functio ning. The mech an ism by wh ich cloza-
pine 's anti-serotonergic e ffec ts might result in a decreased dyskine tic po tenti al,
however, remains to be determined.
By cont rast to clozapine and thioridazine , molindone a nd sulp iride bind
ex tremely weakl y to OJ receptors, to muscarinic cholinergic receptors, to
ad renerg ic receptors and to se rotonergic receptors (4 6, 47). Both mol indone and
sulp ir ide, however, bind potently to a class of dopam ine receptors called
dopamine autoreceptors (OARs). OARs respond directl y to pre-synaptically
rel eased dopamine and serve to inhibit further dopamine release. Blockade of
this negative feedback system effec t ive ly increases th e rate of pre-synaptic
dopamine synthesis and release (52 ). Low dose apomorphine «0.4 mg/kg)
se lec tive ly st im ulates OARs (53). Usin g apomor ph ine to assess DAR function-
ing, it has been found that molindone inhibits DARs 2-4 ti mes more poten tly
than post-synaptic receptors. In th e dose ra nge of 1- 3 mg/kg, molindone
preferentially inhibits OARs (22,54-56). Sulpiride has a lso been shown to
preferentially inhibit OARs, at doses up to 10 mg/kg (2 1,53). C loza pi ne and
thioridazine, as opposed to molindone and sulpiride, appear to antagonize
DAR-mediated activities extremely weakly (53, 54) . OARs have bee n shown to
regulate dopamine release in the nigrostriatal system (59). Agents which act
preferentially on OARs, therefore , would be expecte d not to inhibit a nd possibly
to enhanc e dopaminergic neurotransmi ssion in the striatum. Su ch a n effect
could underlie th e atypical effects of molindone a nd su lp ir ide in animal models
of TO. It should be noted, however, that at high doses molindone and su lpir ide
ca n effectively block postsynaptic dopamine rec eptors. At high doses, therefore ,
these agents might be expected to behave similarly to tradition al neuroleptics.
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In addition to regulating nigrostriatal functioning, OAR s regu late meso-
limbic dopaminergic transmission (52 ,60,6 I) . Stimulation of postsynaptic dopa-
mine receptors with amphetamine or high dose apomorphine has been shown to
induce motor hyperactivity which is mediated via th e mesolimbic system . Low
dose apomorphine, conversely, binds preferentially to OARs, leadi ng to
decreased mesolimbic dopamine release and a charac te r ist ic syndrome of
hypomotility and sedation in rodents (53) . Neither clo zap ine nor thioridazine
reverses the hypomotility induced by low dose apomorphine (53). T hese agents ,
therefore, appear to have littl e ability to reverse mesolimbic dopaminergic
blockade. Conversely su lpiride has been shown to inhibit apomorphine-induced
hypom otility (53) suggesting th at it may not induce net dopaminergic underac-
tivity in the mesolimbic system when administered alone. While th e effec t of
molindone on hypo motility has not been explicitly tested, mol indone ha s been
shown to inh ibi t the effects of low dose apomorphine on dopamine re lease
(54,56) and so wo uld be expected to share su lpiride's behavioral effec ts.
T he relationship between apomorphine-induced hypomotility and sch izo-
phrenic symptomatology remains to be determined. In one stu dy (62), however ,
it was shown that apomorphine-induced hypomotility is accompan ied by a
reward deficit in rats. Untreated rats show an ab ility to increase th eir ra te of bar
pressing when they are sh ifted from a sched u le in whi ch th ey are rewarded with
a food pellet for each response to one in whi ch they are rewarded fo r o nly every
fourth response. After three sessions untreated rats are ab le to obtai n the same
number of pellets as before th e shift in reward sch edule. Rats pretrea ted with
low dose apomorphine , however, fail to significa nt ly a lter their ra te o f
responding following th e sh ift in reward sch edule. Sin ce th e rat s remain
ph ysicall y capable of increasing their responding rat e , th is fa ilure of responding
ma y represent a decreased responsiveness to sec ondary reinforcers. It was
proposed that this decreased re sponsiveness might represent a model for
depressive-like negative schizophrenic sympto ms such as anhedonia and emo-
tional withdrawal. Sulpiride complete ly reverses th e reward deficit induced by
apomorp h ine . Thioridazine, haloperidol , chlorpromazin e and fluphenazine by
contrast fail to reverse the apornophine-induced reward deficit a t any dose.
Molindone has not been explicitly tested in this paradigm.
In man, the mesolimbic system appears to regulate behavioral ac tivity and
mood. Low dose apomorphine produces sedation and sleep and ma y precipitate
severe depression (63 ). Underactivity of th e mesolimbic syste m appears to be
involved in the psychomotor retardation and poor env ironmenta l react ivity seen
in patients with Parkinson's disease (9) and endoge nous depression (64,65).
Furthermore, based upon animal models , it has been po stulated th at OAR-
hypersensitivity, leading to diminished mesolimbic dopam ine release , might be
e t io logic in some forms of retarded depression (66). T he role of OAR s in
humans, th erefore, ma y be simi lar to th eir role in rodents. T he abil ity of
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molindone and sulpiride to preferentially block OARs might predi ct tha t these
agents could preferentially treat th e depressive-like negati ve sym ptoms includ-
ing psychomotor retardation and emotio na l withdrawal.
CLINICAL STUDIES
While the basi c models of T O and negative sym pto ms suggest th at
c1ozapine, thioridazine, su lpir ide and molindone ma y produce atypica l clinical
effects, ultimate confir mat io n or refutation of these predict ions ca n o nly be
obta ined from detail ed clinical stud ies . Sin ce TO generall y de velops 1- 2 years
a fte r the initiation of neuroleptic therapy and occu rs only in a mi nori ty of
subjects (66) , definitive comparison of the relative dyskinetogenic pote ntia l o f
neuroleptics requires long-term longitudinal stud ies of first break schizophrenic
pati ents spanning se vera l yea rs a nd in vol vin g large numbers of subjects . O f th e
four neuroleptics which show atypical effects in animal models, on ly cloza p ine
has been subj ecte d to sufficie n t study to suggest th at it has signi ficant ly lower
dyskinetogenic potential than traditional agents. In one stu dy of 21 6 psyc hiatric
patients treated with clozapine as sole neuroleptic'for up to 12 yea rs no cases of
TO were reported (67 ). Other studies have sim ila r ly show n a decreased d yski-
netic potential for clozapine (68) . Thioridazin e , sulp ir ide an d mol indone , by
contrast , ha ve not been subject ed to suffici ently long-t e rm stu d ies to a llow an
estimation of th eir dyskinetic potential ve rs us traditional agents .
In th e absence of long-term longitudinal stud ies of schizophrenic patients,
"masking" paradigms have been used to try to study th e relat ive dys kinetogenic
potentials of neuroleptic agents. In this approach, subjects are chosen who have
developed persistent withdrawal exacerbated TO. These subjects are ass igned to
different neuroleptic regimens and th e potency with which th ese agents mask
dyskinetic symptoms is determined. Based upon a nima l studies (37,69,70), it ha s
been proposed that those agents which are least potent in masking dys kinet ic
sym pto ms should be lea st likely to induce de novo TO. In a closely rela ted
paradigm, subjects with preexisting TO are exposed to neuroleptics and the
post- vs. pre-exposure severity of TO is determined . Studies usin g th ese
paradigms have been conducted with haloperidol a nd with th e proposed
atypicals clozap ine, thioridazine and molindone . Acti ve treatment with halope r i-
dol has been shown to potently mask dyskinetic symptoms . Subsequent with-
drawal of haloperidol leads to a rebound worsening of dysk ineti c symptoms
sugge st ing th at a progression of the underlying process has occured (69-76) .
Clozapine, by contrast , has been shown to have no sign ifica n t an tidys kine tic
effects and withdrawal of clozapine does not lead to rebound worsening (70, 7 1).
Thioridazine (70 ) and molindone (72) also mask d yskineti c symptoms less
potently than haloperidol does. These agents, however, do produce a significant
degree of masking and therefore cannot be co nside red fr ee of dyskinetogenic
potential. While sulpiride has been shown in humans to have some ability to
mask dyskineti c symptoms (73,74) , its potency has not been directl y co mpared
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e ither to traditional neuroleptics or to other atyp icals . In Cebus monkeys with
persistent neuroleptic-induced orofac ia l d yskinesias su lpiride has been shown to
mask dyskinetic movements to a lesse r degree th an either ha loperidol or
fluph enazin e (75). In addition to c1ozapine , thioridazine (70) and sul piride (75)
do not induce rebound worsening of TO. Addit ionall y, clozapi ne and thiorida-
zine ha ve also been found not to induce rebound worsen ing in Cebus monkeys
with persistent dyskinesias (76) . Molindone has not bee n d irect ly tested in th e
rebound worsening paradigm. T hese stud ies support the basic prediction that
c1ozapine, thioridazin e, sulp ir ide an d molindone have re latively decreased
dyskinetogenic potential when co mpared with traditional agents . Only c1oza-
pine, however, appears inactive in these paradigms, suggesti ng th a t the other
three agents might st ill ha ve sign ifican t although decreased r isks of associated
T O. Furthermore, although thioridazine does not p roduce rebound worsening
of TO in monkeys, two of its metabolites, mesoridazin e a nd su lfo r idazine, have
been shown to induce rebound worsening while a third me tabol ite, thioridazine
ring sulfoxide, does not (69) . Individual metabolism may the re fo re affect
wh ether thioridazine and possibl y o ther neuroleptics have decreased dysk ineto -
genic potential in an y given subject.
Negative symptoms have a lso proven diffi cult to study clinically. No
definitive stud ies ha ve been co nd uc ted wh ich e ither support or re fu te the
suggest ion that sulpiride and molindone shou ld be more efficacious than other
neuroleptics in treating negati ve symptoms . Difficulties arise because negative
sym ptoms have proven diffi cult both to define a nd operat iona lize. In the last few
yea rs, however, phenomenological stud ies ha ve demonst ra ted that depressive-
like negative symptoms (e .g . fatigue , blunted affect a nd loss of inte rest) consti-
tute a cluster of symptoms whi ch are d istinct from e ither positive o r hebephren-
ic-lik e negative sym ptoms (77,78). T he sepa rate clus te r ing of th ese symptoms
suggests that they may be e tio logically di stinct fr om o ther sym ptoms of schizo-
phrenia and may possibl y be mediated by different brain pathways. Operationa l-
ized cr iter ia for negative symptoms have been proposed on ly within th e last few
yea rs (79 ,80). Since no stud ies have di rectl y co mpa red neuroleptics usin g well
validated negative symptom sca les, no firm conclus ions ca n be drawn concerning
the relative effectiveness of typi cal and at ypical neurol eptics in treating nega tive
symptoms. Preliminary conclusions can be drawn , howe ver, fr om medicat ion
tria ls which utilized the Brief Psychiatric Rating Scal e (BPRS) (8 I) . Three BP RS
items, emotional withdrawal, blunted affect, and motor retardation have been
found to correlate with negative symptoms scores but not with positiv e symp-
toms suggesting that they might be useful post-hoc measures of negati ve
symptomatology (77 ,82) . These symptoms are commonly com bined to for m the
withdrawal/retardation subsea Ie (8 I) .
In reviewing three stud ies (83-85) which com pa red clozap ine either to
ba seline or to reference neuroleptic (chlorpromazine or haloperidol), clozapine
significa n tly improved symptoms of withdrawal and retardation in two of the
three. In none of these studies, however, were th e differences significant versus
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a reference neuroleptic. In a fourth study, clozap ine fa iled to im prove an y of th e
BPRS negative sym ptoms (86). Pe rhaps most indicat ive of th e effects of cloza-
pine are the results of a large multicenter European study (87) in whi ch
clozapine was compared with three re ference neurol eptics. While clozapine was
effec tive ov era ll in treating BPRS negative symptoms, no clea r d ifferential effect
was observed. In one subs tudy, clozap ine was superior to ch lorpromazine in th e
treatment of withd rawal/retardat ion . The differential e ffect, however, was less
th an for h yperacti vit y a nd co re symptoms, howe ver, suggest ing that clozapine's
super ior ity was global rather than rest ri ct ed to negative symptoms .
Thioridazine and its acti ve metabolite mesoridazin e have simi larly been
compared with refe rence neuroleptics in a number of stud ies. In three studies
(88-90), thioridazine has been sho wn to be relatively ineffecti ve in ameliorating
emot io nal withdrawal and psychomotor retardation. Mesoridazin e , its active
metabolite, has been shown to be somewhat more effect ive in the t reatme nt of
negative symptoms (89-93) possibl y because it is less seda ting. Mesor idazine
also , however, has been found not to be significan t ly better than reference in
treating negative symptoms. Moreover, in one study in whi ch a ll BPRS symp-
toms improved significantly following treatment with mesoridazine , bl unted
affect and emotiona l withdrawal showed th e least improvement (93) .
Sulpiride ha s been relatively poorly stud ied in trials wh ich employ the
BPRS. In three such studies (94- 96), sulpiride was found to consistently
am eliorate emot iona l withdrawal, motor retardation a nd emot iona l b lunting
along with the subscal e anergia , although in none of these stud ies was su lpiride
sign ifica n t ly superior to the reference neuroleptic (ha lope r idol). However , in
one study whi ch used the Comprehensive Psych opathological Rating Sca le
(C PRS) to compare su ipi ride vers us cholo rpromazine (97), sulp ir ide was found
to be sign ifican tly super io r to chlorp romaz ine in th e treatm ent of autistic
sym ptoms . These symptoms whi ch consisted of inability to fee l, lassitude ,
withdrawal , reduced speech and slow ness of movement are a na logous to BPRS
defined negative sym pto ms but have not been directl y validate d aga ins t them.
While sulpiride and chlorpromazin e both produced sign ifica nt improvement in
global symptomatology and in positive symp toms, su lpir ide sig nificant ly
decreased autistic symptoms whereas chlorpromazine did not. O f interest ,
sulp ir ide-ind uced improvement in negative symptoms was found to be inver se ly
cor re la ted with sulpiride drug concentration such that those subject s with the
highest serum sulpiride concentrations were found to have th e lea st improve-
ment in negative symptoms. Moreover, no significant correlation was fo und
between serum levels of eithe r sulpiride (or ch lo rpromaz ine) and positi ve
sch izop hren ic symptoms. Since the dosage of sulpiride used in the last study (800
mg/day) was significantly less than the dosages in the three stud ies emp loying
th e BPRS (1200-1600 mg/d mean final dosage) th e differences in outcome
might be related to the dosage differences. Two other uncontroll ed studies have
also suggested that sulpiride may have anti-autistic effec ts a t dosages of 800 (98)
and 600- I 200 (99) mg/day. These stud ies, therefore , suggest th at low dose
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su lp ir ide may have rela t ive ly improved efficacy in treati ng negative symptoms
a lthoug h at high doses th is diffe rent ial effect may be lost.
O f 16 clinical tria ls with molindone, 7 have compared it to a referen ce
neuroleptic using the BPRS (100- 106) . O f these, six demonstrated improve-
ment either in the items; emotional withdrawal, motor retardation and blunted
affect or in the withdrawal/re tardation subscale whic h encompasses these items.
O f th e fo ur studies whic h measured the wit hdrawal/retardation subscal e explic-
itly (103- 106), all four demonstrated a significant response of these symptoms to
molindone but no t to refere nce neuroleptic. In th ree of these stu d ies, th e
p referential effects of mol indone on negative symptoms were statisticall y signifi-
cant. These studies support the prediction based upon animal models th at
mol indone may be superior to traditional neuroleptics in th e treatment of
negative symptoms.
T HERA PEUTIC IMPLI CAT IO NS
T hese clinica l studies support the animal model-based predictions th at
clozapine, th ioridazine, mol indone , and su lpiride may have relatively decreased
dyskinetogenic potential compared with traditional agents. Only clozapine ,
however, appears completely free of associated TO. Of the four at ypical agents,
on ly two , th ioridazine and molindone, are currentl y available for non-
ex per imenta l use in the U .S. T hese agents appear to differ in the me chanism of
their atyp ica lity and in th e ir cl inical effects. T hioridazine which is a re latively
sedating ne urolept ic with no apparent specific efficacy in treating negative
symptoms appears to be more clozapine-like in its mechanism of atypicality.
Molindone, conversely, more closely resembles the proposed at ypical agent
sulpiride and appears to prod uce atypical clin ica l effects by virtue of its ability to
se lective ly block presyna ptic dopami ne autoreceptors (OARs). Molindone , like
su lp ir ide, has been shown to be rela tively more effective in treating negative
symptoms of sch izophrenia tha n tradit ional neuroleptics. A theoretical concern
wit h mol indone is that, like sulpi ride , it may lose its atypicality at high dosages.
In an imal studies, mol indone has been shown to lose some degree of atypicality
at dosages over 3 mg/kg (24,25). Whether a similar therapeutic window exists
clinically remains to be de te r mined .
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